The TrkA receptor is a 140 kDa transmembrane glycoprotein with tyrosine kinase activity that functions as the nerve growth factor (NGF) receptor (Kaplan et al., 1991; Klein et al., 1991) . NGF also binds with low affinity to a ~75 receptor the signaling function of which is unclear (Chao, 1992) . Homodimers of TrkA or heterodimers of TrkA and ~75 bind NGF with higher affinity (Hempstead et al., 1991; Jing et al., 1992; Mahadeo et al., 1994) , suggesting that specific receptor conformations may play specific functions.
TrkA protein or mRNA are expressed in neural crest-derived sensory and sympathetic neurons, possibly in cholinergic neurons (Cavicchioli et al., 1991) , within the basal forebrain and striatum (Holtzman et al., 1992; Verge et al., 1992) , and in some nonneuronal tissues (Chevalier et al., 1994) . Functional studies of neuronal cultures in vitro have suggested that TrkA protein is expressed throughout the cell surface (Campenot et al., 1994) . However, whether this also is true within the architecture of the brain remains to be established.
NGF promotes the differentiation of certain neuronal cells, is mitogenic for TrkA-transfected fibroblasts, and allows survival in serum-deprived conditions for both cell types. Activation of the tyrosine kinase activity of TrkA via NGF binding leads to receptor trans-and auto-tyrosine phosphorylation (PY), and PY of second messengers including phosphatidylinositol-3 kinase (PI-3 kinase) (Soltoff et al., 1992) . PI-3 kinase is involved in protein trafficking and endocytosis of ligand-receptor complexes (for review, see Kaplan and Stephens, 1994) . Because microinjection of NGF into %cei ved June 21, 1995; rev&d Nov. 9, 1995; accepted Nov. 17, 1995 (Heumann et al., 1984) , cell-surface receptor ligation and internalization of TrkA or NGF-TrkA complexes must mediate these effects. TrkA, like most kinase growth factor receptors, signals through receptor oligomerization (Heldin, 1995) . Thus, monovalent TrkAbinding agents are antagonistic or have no biological effects (Clary et al., 1994; LeSauteur et al., 1995) , whereas bivalent receptorbinding agents such as NGF (a homodimer; Bradshaw et al., 1993) or antibodies can be agonistic. The principle of using polyclonal antibodies to activate neural receptors has been demonstrated previously (Clary et al., 1994; Twyman et al., 1995) . In contrast, only a limited number of anti-receptor monoclonal antibodies mimic ligand functions (Galloway et al., 1992; Taub and Greene, 1992) , and none exists against neurotrophin receptors. In this study, we report the development and characterization of an agonistic anti-human TrkA mAb 5C3 that recognizes the NGF-docking site. mAb 5C3 was used to characterize the pattern of TrkA protein expression in normal human brain and the NGF-binding features of the receptor. mAb 5C3 behaves like NGF in bioassays, and monomeric 5C3 F,,s retained binding and functional agonistic activity. mAb 5C3 will be useful to identify the NGF-docking site on TrkA and possibly as a pharmacological lead in the development of small mimetics. . , serum (Upstate biotechnology) were purchased commercially, mouse anti-rat p75 mAb MC192 ascites were a gift from P. Barker, and anti-p65 mAb 87.92.6 (Co et al., 1985) was grown in our laboratory. saturation is evident at 2 pg/ml mAb X3, at which concentration the fluorescence intensity is maximal. Similar analysis with mAb 5C3 Fahs demonstrated that specificity (data not shown) and saturability were similar to that obtained with intact mAb. Lower F,, protein concentrations (0.7 pg/ml) were required for receptor saturation (Fig. 1B) . Because the molecular weight of 5C3 F,, is threefold lower than 5C3 IgG (-50 vs -150 kDa, respectively), equimolar concentrations of IgG and F,, ligands were required to saturate hTrkA.
MATERIALS AND METHODS Antibodies

LOG FLUORESCENCE INTENSITY
Western blot analysis with mAb 5C3 revealed heterogeneous material of A4, 140 kDa (~140) for samples from E25 and 4-3.6 cells but not for control cells (Fig. 2A) . In these cells, a band of -110 kDa (~110) was also observed, previously thought to be intracellular TrkA precursors (Martin-Zanca et al., 1989) . The ~140 band also was immunoblotted in samples dissected from normal human cortex or nucleus basalis of Meynert (Fig. 2s) . The ~110 band was not seen, perhaps because of different posttranslational processing in neuronal tissues with respect to transfected cell lines. mAb 5C3 was effective in Western blot analysis only when samples were prepared under nonreducing conditions, indicating that a disulfide bond-stabilized conformational epitope is recognized. lmmunostaining in normal human brain mAb 5C3 was used to map TrkA protein expression by immunocytochemistry of normal adult human brains. The striatum, basal forebrain, and brainstem exhibited the strongest immunostaining, whereas only weak staining could be detected in the cerebral cortex and hippocampal formation (Fig. 3 ). All sectors of the basal nucleus contained large TrkA-positive neurons (Fig. 3A,C) , most of them in groups embedded in a dense network of overlapping stained processes (Fig. 3A) . The cells had heterogeneous shapes, ranging from complex multipolar to fusiform. ure 30 shows typical labeled multipolar neurons that displayed strong granular immunoreactivity around the nucleus and in proximal processes. Moreover, numerous puncta and varicose fiber fragments were observed in these areas. ?he globus pallidus and claustrum were mostly negative except for varicose fibers. Similarly, the interstitial elements and fiber bundles did not contain reactive fibers, whereas the internal capsule displayed some labeled punctas and fibers, particularly near the putamen and caudate nucleus.
In the basal ganglia, TrkA was detected in distinct cellular compartments.
The caudate nucleus, nucleus accumbens, and putamen contained several immunoreactive cell bodies without apparent distinction in density, perikaryal staining, or shape. Fig- The hippocampal formation showed weak immunostaining located principally in scattered fibers and puncta in the stratum granulosum of the dentate gyrus, as well as in the strata oriens and pyramidale of Ammon's horn. In addition, some weakly stained perikarya could be observed in the stratum pyramidale of the CA2 and CA3 subfields of Ammon's horn and in the hilus of the dentate gyrus (CA4 subfield; Fig. 3E Table 3 ).
In the converse experiment, mAb 5C3 inhibited -60% of ["'I]NGF binding to E25 cells. In these experiments, background binding was assessed by blocking with 5 FM NGF (100% inhibition), and maximal binding was assessed with binding buffer vehicle only (0% inhibition) or by using irrelevant binding mAb 87.92.6 (Table 2 ).
Functional agonism of mAb 5C3 Several functional assays of NGF bioactivity were used to test the agonistic potential of mAb 5C3.
Receptor internalization The 4-3.6 cells were treated with TrkA ligands at internalizationpermissive temperatures (37°C) or at nonpermissive temperatures (4°C ; Table 3 ). NGF treatment reduced the percent staining of mAb 5C3 to surface TrkA at both temperatures. Loss of surface 5C3-binding sites suggests direct blocking by NGF (see also Fig.  4 ). In contrast, mAb 5C3 treatment reduced the number of surface 5C3-binding sites only at 37°C. This is likely attributable to receptor internalization, which does not occur efficiently at 4°C. Treatment with mIgG or binding buffer control did not reduce the number of surface 5C3-binding sites at either temperature. Similar data were obtained with E25 cells (data not shown).
Receptor PY Anti-phosphotyrosine Western blots of E25 or 4-3.6 whole-cell detergent extracts revealed that TrkA PY increased significantly over basal levels after short treatment with mAb 5C3 or with NGF (Fig. 5) . Densitometric analysis of several blots from E25 and 4-3.6 cells is presented in Table 4 . Other proteins, including -95 and -60 kDa proteins and the ~85 subunit of PI-3 kinase (-2.5-fold increase; data not shown), also showed increased PY. We have estimated that <lo% of all ~85 material was tyrosinephosphorylated after ligation of TrkA.
Increased cellular transformation NGF treatment causes the transformation and an increase in anchorage-independent growth of TrkA-expressing E25 cells (Cordon-Card0 et al., 1991) . mAb 5C3 caused an approximately twofold increase in the number and size of foci compared with mIgG-treated cells ( perikarya of these neurons were relatively large, of ovoid to pyramidal shape, and bearing one prominent apical and radial dendritic process. The immunoreactivity appeared, as in other stained cell types of the brain, as small granular patches of precipitate located principally near the nuclear envelope and in some cases within the cytoplasm (Fig. 3E) . Within the cerebral cortex, particularly in the frontal area, TrkA immunoreactivity appeared more discrete. At high magnification, immunoreactive puncta and fiber fragments without a particular pattern of distribution are observed in all layers, but laminae III-VI appeared more stained than superficial ones (Fig.  3H) . Weakly staining, medium-sized perikarya were occasionally observed in layer IV (Fig. 3H) .
In the brainstem, TrkA staining also is detected. The pontine nuclei contained numerous immunoreactive, medium-sized globular perikarya and fibers between the pontocerebellar fibers (Fig.  3F) . The reticular formation also displayed strong immunoreactivity for TrkA principally located in fiber networks (Fig. 3G) . Some large neurons of bipolar or multipolar shape also are In three independent experiments, the average Kd of mAb 5C3 in E25 cells was 1.6 nM. Competition with NGF reduced the average number of X3-binding sites, but the affinity of mAb 5C3 was not affected. surviving/proliferating E25 fibroblastoid cells (Fig. 6 ). Equivalent protection also was afforded by TrkA ligands to neuronal 4-3.6 cells (data not shown). In most experiments, mAb 5C3 protection is dose-dependent, although high-dose antibody inhibition sometimes is seen (e.g., 1 pg/ml mAb X3).
To ascertain whether cell death is apoptotic, DNA was prepared from serum-free cultured cells that showed a typical apoptotic fragmentation ladder. The DNA ladder was not seen in preparations from cells cultured in the presence of mAb 5C3 or NGF (data not shown).
Controls demonstrated the functional specificity of m.Ab X3. First, neither NGF nor mAb 5C3 protected wild-type NIH-3T3 cells (data not shown). Second, PC12 cells were not protected by mAb 5C3 but were protected by NGF (data not shown). Third, irrelevant mIgG, GarmFar,, or mAb 192 did not protect E25 cells (Fig. 6) or NIH-3T3 cells (data not shown).
Functional agonism of monomeric 5C3 Fabs Monovalent agents that bind TrkA behave as competitive antagonists (Clary et al., 1994; LeSauteur et al., 1995) likely because they cannot induce receptor dimerization. Therefore, it would be expected that monomeric 5C3 Fabs would be monovalent and not be able to mediate agonistic function. mAb 5C3 F,,s afforded protection from apoptotic death to E25 cells (Fig. 6 ) and 4-3.6 cells (data not shown) in SFM. Moreover, anti-phosphotyrosine Western blots revealed that cells treated with 5C3 Fabs had increased T&A-PY similar to increases obtained with whole mAb 5C3 (data not shown). Monomeric 5C3 F,, protection was dose-dependent. However, equivalent or better protective effects were achieved when Fabs were cross-linked externally with GomF, antibodies. Specificity controls included those described in the previous section for whole mAb 5C3, plus 192 F,s that had no protective activity in E25 cells (data not shown).
DISCUSSION
The availability of antibodies against ~140 TrkA and ~75 has allowed the study of these NGF receptors (Martin-Zanca et al., 1989; Eager, 1991) . The mAb 5C3 reported in this study is specific for human TrkA and functions in FACScan immunofluorescence analysis, immunoprecipitation, Western blot analysis, and immu- Figure 6 . Protection from apoptotic death by 5C3. E25 cells were cultured in SFM supplemented with the indicated conditions for 2-3 d, followed by the MTT assay. Similar data were obtained with neuronal 4-3.6 cells (data not shown). The percent proliferation/survival i SD was determined by standardizing serum-containing wells to 100% using the following formula: [(optical density of test) X lOO%]/(optical density of serum).
nocytochemistt-y. Moreover, mAb X3 is a structural and functional mimic of NGF. Aberrant expression of t&A mRNA and NGF responsiveness have been correlated with neurodegenerative disorders (for review, see Ebendal et al., 1991) and neoplastic malignancy (Marchetti et al., 1993; Matsushima and Bogenmann, 1993) . Hence, TrkA-binding agents will be useful clinical tools in diagnosis, prognosis, and perhaps treatment of these diseases. Indeed, mAb X3 binding is a positive prognostic marker for certain human neoplasias (K. Kramer, unpublished observations).
mAb 5C3 was used to map the distribution of TrkA protein in the normal human brain postmortem. The data are consistent with the distribution of t&A mRNA and ~140 TrkA protein previously described in numerous neurons of the basal forebrain and striatum (Holtzman et al., 1992; Steininger et al., 1993; Allen et al., 1994; Martinoff et al., 1994) . Moreover, the present study has revealed TrkA immunostaining in other cell types of the human brain including the hippocampal formation, cerebral cortex, and brainstem.
The presence of equivalent levels of TrkA protein (per weight of tissue) in the cortex and the nucleus basalis of Meynert was further supported biochemically by Western blot analysis. Quantitative differences between ilz situ mRNA hybridization and immunostaining may reflect increased sensitivity of the mAb 5C3, long TrkA protein half-life, post-transcriptional control of expression, or instability of the mRNA.
Correlation between TrkA and choline acetyltransferase immunostaining (Mesulam and Geula, 1991; De Lacalle et al., 1994) suggest that most TrkA-labeled perikarya express the cholinergic phenotype. This was confirmed by studies of colocalization (Steininger et al., 1993; Martinoff et al., 1994) . However, our results indicate that some TrkA-positive cells are not cholinergic, because the hippocampal formation does not contain intrinsic cholinergic cells in the human brain (De Lacalle et al., 1994) . mAb 5C3 recognizes a disulfide-stabilized domain of T&A, and an extracellular epitope with these characteristics appears to be the NGF-docking site (Perez et al., 1995; Urfer et al., 1995 (Sibanda et al., 1989) and, coincidentally, the NGF structures that bind TrkA also may be p-turns (LeSauteur et al., 1995) , we hypothesized that both mAb 5C3 and NGF bind to the same site on human TrkA, and cross-blocking is likely to be caused by direct competition rather than steric hindrance.
Interestingly, mAb 5C3 was more efficient at blocking NGF binding than vice versa. Only -25% of the mAb 5C3-binding sites on E25 fibroblasts were blocked by saturating doses of NGF. These data suggest that not all TrkA receptors in this transfected cell line bind NGF. It is unlikely that affinity considerations can account for these observations, because both ligands have roughly comparable Kd for TrkA (mAb 5C3, Kd -1.6 nM; NGF, Kd = 0.7 nM; Jing et al., 1992) and the affinity of mAb 5C3 was unchanged in the presence of NGF.
Three nonexclusive possibilities can account for these observations: (1) TrkA receptors exist at equilibrium, at which -25% are in an NGF-binding conformation (e.g., dimers) and the rest are in a non-NGF-binding conformatiom (2) specific post-translational modifications of TrkA receptors allow for NGF binding; and/or (3) expression of other membrane proteins [e.g., ~75 or an unknown protein(s)] induces or favors the NGF-binding conformation of TrkA. These hypotheses can be addressed by biochemical analysis after differential affinity purification of TrkA with mAb 5C3 versus NGF and by further binding studies in neuronal and fibroblastoid cells expressing different receptors.
The absence of mAb 5C3 binding to rat TrkA is intriguing. Binding by mAb 5C3 to rat TrkA was expected because of the homology between mAb 5C3 CDRs and the variable loops of NGF, particularly because NGF from one species does bind to T&As from other species. mAb 5C3 is a binding and structural mimic of NGF, with enhanced human receptor specificity. Remodeling and mutating of the CDRs of mAb 5C3 will yield a pan-TrkA-binding mAb. Furthermore, analysis of the epitope of mAb 5C3 on TrkA likely will reveal differences in the docking sites of human and rat T&As. This information will be useful in screening receptor-binding analogs. To test functional mimicry by mAb 5C3, NGF bioassays were performed using trlul-transfected fibroblast and neuronal cells. Functional mimicry by mAb 5C3 included TrkA internalization, TrkA-PY, PI-3 kinase PY, increased anchorage-independent growth, and proliferation/survival of cells in SFM. By these criteria, mAb 5C3 is agonistic.
Increased T&A-receptor turnover or internalization is induced by NGF binding. mAb 5C3 increased the internalization of T&A, as measured by loss of cell-surface receptors. These results are consistent with data that showed that E25 cells internalize [lz51]NGF within seconds after shifting from 4 to 37°C (Jing et al., 1992) and that this process does not require p75 receptors. Thus, artificial ligands of TrkA can induce receptor internalization and could be useful in delivering toxic agents to the cytoplasma of TrkA-expressing tumors. NGF ligation of TrkA causes receptor activation and autophosphorylation.
mAb 5C3 induced TrkA-PY to a similar degree. Agonism in the absence of NGF suggests that TrkA dimerization and/or internalization is the required signaling event, rather than the formation of NGF-TrkA complexes. However, we cannot rule out that mAb 5C3-TrkA may be the functional signal-transducing complex.
Ligand-induced PY of the intracellular domain of TrkA allows for the recruitment of substrates and the activation of cytosolic proteins and nuclear oncoproteins. mAb 5C3 induces the PY of proteins of M, 60, 85, and 95 kDa. The 85 kDa protein was identified as PI-3 kinase, the activation of which correlates with the actions of growth factors and oncogenes.
NGF stimulates neuronal survival and differentiation (for review, see Barbacid, 1994) and the proliferation of non-neuronal cells (Marchetti et al., 1993) . NGF-activated TrkA induces transformation and morphological changes in fibroblast cells (CordonCardo et al., 1991) . mAb 5C3 caused similar increases in anchorage-independent growth and foci formation in soft agar. Thus, mAb 5C3 can positively modulate the growth of TrkAexpressing cells. Interestingly, the size of the mAb 5C3-induced foci were larger on average than NGF-induced foci. We currently are investigating possibilities that may account for this observation.
T&&expressing neuronal 4-3.6 cells or fibroblastoid E25 cells undergo apoptotic death in SFM but can be rescued by NGF or mAb 5C3. Synergy between the two ligands occurred when combined at suboptimal doses (data not shown), as would be expected if mAb 5C3 bound and activated unoccupied TrkA receptors. Furthermore, morphological changes and increased attachment to plastic were observed in both NGF-and 5C3-treated cells.
Monomeric X3 F,,s protected E25 and 4-3.6 cells from apoptotic death. When Fabs were cross-linked externally using anti-F,, antibodies, a heightened response occurred. Because growth factor-receptor activation requires bivalent binding (Clary et al., 1994; Heldin, 1995) the monomeric 5C3 F,,s must have retained the ability to induce TrkA oligomerization.
This could be explained in the following three ways: (1) F,,s are relatively large molecules capable of aggregation; (2) 5C3 F,, binding could cause conformational changes in TrkA that induce receptor-receptor interactions; and (3) monomeric 5C3 Fabs bind to two receptor molecules in a bivalent manner. The last possibility could occur by two CDRs binding to two different T&As. Homology of mAb 5C3 CDRs to NGF turn regions and experiments using small recombinant antibody analogs (S. Maliartchouk and H. Saragovi, unpublished observations) support the third explanation. mAb 5C3 is the first reported agonistic anti-neurotrophin receptor mAb and will be useful in studies of TrkA biology and for drug development. Antineoplastic effects with mAb 5C3 may be achieved through terminal differentiation, antibody-dependent cell cytotoxicity, or by the delivery of toxins or radionuclides. Furthermore, the structure of this mAb may be useful in designing peptidic and nonpeptidic T&A-binding agents (Saragovi et al., 1991) . Small, nonpeptidic agonists of TrkA should be useful pharmacological agents for the treatment of neurodegenerative diseases.
